Published in Blood on November 01, 1992
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Myeloma as a model for the process of metastasis: implications for therapy. Blood (2012) 1.36
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood (2008) 1.24
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res (2012) 1.14
Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood (2007) 1.03
Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med (1994) 1.03
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood (2011) 0.97
The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood (2010) 0.95
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt (2011) 0.92
A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther (2009) 0.87
The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest (1998) 0.86
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Cell Trafficking in Multiple Myeloma. Open J Hematol (2012) 0.79
Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med (2016) 0.78
Integrin expression on neutrophils in a rabbit model of Group B Streptococcal meningitis. Inflammation (2000) 0.77
In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins. Leukemia (2015) 0.77
Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS One (2012) 0.76
Mixed Fibronectin-Derived Peptides Conjugated to a Chitosan Matrix Effectively Promotes Biological Activities through Integrins, α4β1, α5β1, αvβ3, and Syndecan. Biores Open Access (2016) 0.75
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2001) 2.39
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Location of BRCA1 in human breast and ovarian cancer cells. Science (1996) 1.88
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol (1998) 1.80
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol (1997) 1.68
Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol (1999) 1.64
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 1.61
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 1.59
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 1.59
Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant (2000) 1.57
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood (2001) 1.57
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia (2008) 1.56
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med (1993) 1.46
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene (2007) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion (1996) 1.44
Leukocyte reduction in blood component therapy. Ann Intern Med (1992) 1.44
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet (1988) 1.43
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res (1997) 1.42
The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood (1997) 1.42
Trichotillomania and trichophagia leading to trichobezoar. J Dermatol (2000) 1.41
Antigens on human plasma cells identified by monoclonal antibodies. J Immunol (1983) 1.41
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol (1985) 1.35
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem (2000) 1.31
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer (2006) 1.25
Mechanical properties of the colon: comparison of the features of the African and European colon in vitro. Gut (1985) 1.24
Pneumococci relatively resistant to penicillin: a prevalence survey in children. J Pediatr (1980) 1.22
Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol (2001) 1.22
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood (1999) 1.21
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest (1982) 1.21
Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol (2005) 1.20
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest (1987) 1.18
Bortezomib as an antitumor agent. Curr Pharm Biotechnol (2006) 1.17
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem (2001) 1.16
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia (2011) 1.16
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood (1999) 1.15
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother (2001) 1.15
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol (2004) 1.14
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A (1996) 1.13
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia (2010) 1.12